Dipartimento di Medicina Interna e Specialità Mediche, University of Rome, Sapienza, Rome, Italy.
Division of Endocrinology, Diabetes, and Metabolism, The Johns Hopkins School of Medicine, Baltimore, MD, USA.
Lancet Diabetes Endocrinol. 2018 Jun;6(6):500-514. doi: 10.1016/S2213-8587(17)30325-X. Epub 2017 Nov 5.
Follicular thyroid cancer is the second most common differentiated thyroid cancer histological type and has been overshadowed by its more common counterpart-papillary thyroid cancer-despite its unique biological behaviour and less favourable outcomes. In this Review, we comprehensively review the literature on follicular thyroid cancer to provide an evidence-based guide to the management of these tumours, to highlight the lack of evidence behind guideline recommendations, and to identify changes and challenges over the past decades in diagnosis, prognosis, and treatment. We highlight that correct identification of cancer in indeterminate cytological samples is challenging and ultrasonographic features can be misleading. Despite certain unique aspects of follicular thyroid cancer presentation and prognosis, no specific recommendations exist for follicular thyroid cancer and Hürthle cell carcinoma in evidence-based guidelines. Efforts should be made to stimulate additional research in this field.
滤泡性甲状腺癌是第二常见的分化型甲状腺癌组织学类型,尽管其具有独特的生物学行为和较差的预后,但它被更为常见的乳头状甲状腺癌所掩盖。在这篇综述中,我们全面回顾了滤泡性甲状腺癌的文献,旨在为这些肿瘤的管理提供循证指导,强调指南推荐背后缺乏证据,并确定过去几十年在诊断、预后和治疗方面的变化和挑战。我们强调,在不确定的细胞学样本中正确识别癌症具有挑战性,超声特征可能具有误导性。尽管滤泡性甲状腺癌的表现和预后存在某些独特方面,但在循证指南中并没有针对滤泡性甲状腺癌和 Hurthle 细胞癌的具体建议。应该努力在这一领域激发更多的研究。